Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection

Abrishami, Mojtaba; Abrishami, Majid; Mahmoudi, Asma; Mosallaei, Navid; Roodi, Mohammad Vakili Ahrari; Malaekeh‐Nikouei, Bizhan

doi:10.1155/2016/1368481

Cited by 25 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biodegradable implants [75], non-biodegradable implants [76], biodegradable microspheres [71], nanoparticles [77], dendrimers [78], and hydrogels [79] have been used for intravitreal drug administration. Moreover, some sophisticated systems have been developed for the treatment of chronic and refractory ocular diseases, such as a microelectromechanical systems (MicroPump) [80] and a port delivery systems (PDS) [81].…”

Section: Posterior Routementioning

confidence: 99%

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

et al. 2020

View full text Add to dashboard Cite

The treatment of the posterior-segment ocular diseases, such as age-related eye diseases (AMD) or diabetic retinopathy (DR), present a challenge for ophthalmologists due to the complex anatomy and physiology of the eye. This specialized organ is composed of various static and dynamic barriers that restrict drug delivery into the target site of action. Despite numerous efforts, effective intraocular drug delivery remains unresolved and, therefore, it is highly desirable to improve the current treatments of diseases affecting the posterior cavity. This review article gives an overview of pharmacokinetic and biopharmaceutics aspects for the most commonly-used ocular administration routes (intravitreal, topical, systemic, and periocular), including information of the absorption, distribution, and elimination, as well as the benefits and limitations of each one. This article also encompasses different conventional and novel drug delivery systems designed and developed to improve drug pharmacokinetics intended for the posterior ocular segment treatment.

show abstract

Section: Posterior Routementioning

confidence: 99%

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The purpose of proposing drug-loaded SLNs is to overcome the drawbacks associated with other colloidal carriers, such as liposomes. Indeed, compared to liposomes, SLNs have numerous advantages, including an easy and economical preparation without the use of organic solvents [ 84 , 86 , 87 ]. SLNs consist of solid fats (in the range 0.1–30% by weight) dispersed in an aqueous phase.…”

Section: Methods Of Loading Active Principles Into Contact Lensesmentioning

confidence: 99%

Contact Lenses as Ophthalmic Drug Delivery Systems: A Review

Franco

Marco

2021

Polymers

View full text Add to dashboard Cite

Ophthalmic drugs used for the treatment of various ocular diseases are commonly administered by eye drops. However, due to anatomical and physiological factors, there is a low bioavailability of the active principle. In order to increase the drug residence time on the cornea to adequate levels, therapeutic contact lenses have recently been proposed. The polymeric support that constitutes the contact lens is loaded with the drug; in this way, there is a direct and effective pharmacological action on the target organ, promoting a prolonged release of the active principle. The incorporation of ophthalmic drugs into contact lenses can be performed by different techniques; nowadays, the soaking method is mainly employed. To improve the therapeutic performance of drug-loaded contact lenses, innovative methods have recently been proposed, including the impregnation with supercritical carbon dioxide. This updated review of therapeutic contact lenses production and application provides useful information on the most effective preparation methodologies, recent achievements and future perspectives.

show abstract

“…These nanocarriers can encapsulate micromolecules, siRNA, DNA, and proteins. Abrishami et al injected solid lipid nanoparticle-conjugated diclofenac intravitreally and found that mild improvement in drug efficacy occurred in the intraocular space [ 102 ]. After sunitinib-encapsulated solid lipid nanoparticles were administered intravitreally into rabbit eyes, drug efficacy was enhanced [ 103 ].…”

Section: Efforts To Enhance the Intraocular Pharmacokinetics And Pmentioning

confidence: 99%

Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives

2021

View full text Add to dashboard Cite

Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growth factor intravitreal injection methods. However, because intravitreal treatment requires monthly or bimonthly repeat injections to achieve optimal efficacy, recent investigations have focused on extended drug delivery systems to lengthen the treatment intervals in the long term. Dose escalation and increasing molecular weight of drugs, intravitreal implants and nanoparticles, hydrogels, combined systems, and port delivery systems are presently under preclinical and clinical investigations. In addition, less invasive techniques rather than intravitreal administration routes, such as topical, subconjunctival, suprachoroidal, subretinal, and trans-scleral, have been evaluated to reduce the treatment burden. Despite the latest advancements in the field of ophthalmic pharmacology, enhancing drug efficacy with high ocular bioavailability while avoiding systemic and local adverse effects is quite challenging. Consequently, despite the performance of numerous in vitro studies, only a few techniques have translated to clinical trials. This review discusses the recent developments in ocular drug delivery to the retina, the pharmacokinetics of intravitreal drugs, efforts to extend drug efficacy in the intraocular space, minimally invasive techniques for drug delivery to the retina, and future perspectives in this field.

show abstract

Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection

Cited by 25 publications

References 22 publications

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

Contact Lenses as Ophthalmic Drug Delivery Systems: A Review

Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives

Contact Info

Product

Resources

About